This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARDM Aradigm (ARDM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aradigm Stock (NASDAQ:ARDM) 30 days 90 days 365 days Advanced Chart Get Aradigm alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.15▼$0.3852-Week Range N/AVolumeN/AAverage Volume97,091 shsMarket Capitalization$761 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California. Read More Receive ARDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aradigm and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDM Stock News HeadlinesFirst International Bank of Israel Ltd (FIBI)November 21, 2023 | investing.comAltshuler Shaham Financial LTD (ALTF)November 10, 2023 | investing.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. | Porter & Company (Ad)Non-Cystic Fibrosis Bronchiectasis Market Forecast to 2030April 30, 2023 | marketwatch.comAerodrome Group Ltd (ARDM)April 22, 2023 | investing.comAerodrome Group Ltd (ARDM.TA)March 17, 2023 | finance.yahoo.comHow and Why Google Glass FailedDecember 27, 2022 | investopedia.comSee More Headlines ARDM Stock Analysis - Frequently Asked Questions How were Aradigm's earnings last quarter? Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings data on Thursday, November, 15th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The business had revenue of $0.28 million for the quarter. What other stocks do shareholders of Aradigm own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aradigm investors own include Amarin (AMRN), Anavex Life Sciences (AVXL), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), Vaxart (VXRT), Aduro Biotech (ADRO) and Altimmune (ALT). Company Calendar Last Earnings11/15/2018Today7/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:ARDM CIK1013238 Webwww.aradigm.com Phone510-265-9000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.70 million Net Margins-374.80% Pretax MarginN/A Return on EquityN/A Return on Assets-374.15% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual Sales$14.47 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / BookN/AMiscellaneous Outstanding Shares15,220,000Free FloatN/AMarket Cap$761 thousand OptionableOptionable Beta1.57 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ARDM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aradigm Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aradigm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.